News

2

Jul, 2020

New paper published in WHO Bulletin

Tags:

Our collaborator Prof. Mike Sharland, together with GARDP and St. George’s, University of London researchers have just published a new paper in the WHO Bulletin investigating international antibiotic sales data of child-appropriate oral formulations of antibiotics, with a focus on dispersible tablets.

READ MORE

21

Apr, 2020

An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial

Tags: , ,

Authors: Hill LF, Turner MA, Lutsar I, et al; NeoVanc Consortium. Published in: Trials. 2020;21(1):329 Background Vancomycin has been used in clinical practice for over 50 years; however, validated, pharmacokinetic (PK) data relating clinical outcomes to different dosing regimens in neonates are lacking. Coagulase negative staphylococci (CoNS) are the most commonly isolated organisms in neonatal, late–onset sepsis (LOS). Optimised use to maximise efficacy while minimising toxicity and resistance selection is imperative to ensure vancomycin‘s continued efficacy. Methods NeoVanc is a European, open-label, Phase IIb, randomised, controlled, non-inferiority trial comparing an optimised vancomycin regimen […]

READ MORE

10

Jan, 2020

Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review

Tags: ,

Authors: Donà D, Barbieri E, Daverio M, Lundin R, Giaquinto C, Zaoutis T, Sharland M Published in: Antimicrob Resist Infect Control.2020;9:3 Background Antibiotics are the most common medicines prescribed to children in hospitals and the community, with a high proportion of potentially inappropriate use. Antibiotic misuse increases the risk of toxicity, raises healthcare costs, and selection of resistance. The primary aim of this systematic review is to summarize the current state of evidence of the implementation and outcomes of pediatric antimicrobial stewardship programs (ASPs) globally. Methods MEDLINE, Embase and Cochrane Library databases were systematically searched […]

READ MORE

30

Dec, 2019

Standardising neonatal and pediatric anitibiotic clinical trial design and conduct: the PENTA-ID network review

Tags: , ,

Authors: Folgori L, Lutsar I, Standing JF, et al. Published in: BMJ Open. 2019; 9:e032592 Abstract: Antimicrobial development for children remains challenging due to multiple barriers to conducting randomised clinical trials (CTs). There is currently considerable heterogeneity in the design and conduct of paediatric antibiotic studies, hampering comparison and meta-analytic approaches. The board of the European networks for paediatric research at the European Medicines Agency (EMA), in collaboration with the Paediatric European Network for Treatments of AIDS-Infectious Diseases network (www.penta-id.org), recently developed a Working Group on paediatric antibiotic CT design, involving academic, regulatory […]

READ MORE

28

May, 2019

Article – “R&D for children’s antibiotics: a wake-up call” published in AMR Control

Tags: , , ,

We are delighted to see  an article on children’s antibiotics, co-authored by GARDP R&D Director, Dr Seamus O’Brien, Penta’s Chief Scientific Officer, Prof. Theo Zakoutlis and Prof. Mike Sharland, from St. George’s, University of London, published in AMR Control, as governments have been discussing AMR at the World Health Assembly.

READ MORE